title: Managing the neuropsychiatric complications of hepatitis C treatment.
abstract: Interferon-alpha is the mainstay of hepatitis C treatment and has been linked to several neuropsychiatric complications, including depression, anxiety, mania, psychosis and cognitive changes. This article reviews the management of neuropsychiatric adverse effects and the risks of interferon-alpha treatment to psychiatric patients.
authors.affiliation: Department of Psychiatry, Centre for Addiction and Mental Health, Toronto, ON.
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Sockalingam
authors.forename: Chekkera
authors.initials: C
authors.lastname: Shammi
authors.forename: Vicky
authors.initials: V
authors.lastname: Stergiopoulos
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000139:chemically induced / Q000188:drug therapy; D003072:Cognition Disorders / Q000139:chemically induced / Q000188:drug therapy; D003866:Depressive Disorder / Q000139:chemically induced* / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011605:Psychoses, Substance-Induced / Q000188:drug therapy / Q000209:etiology; D011994:Recombinant Proteins; D012307:Risk Factors
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a